From Report on Medicare Compliance - C.R. Bard Inc. has agreed to pay $48 million to settle false claims allegations over its sale of brachytherapy seeds, a form of radiation therapy for prostate cancer, the Department of Justice said May 13. C.R. Bard allegedly induced hospitals and physicians to buy its seeds by giving them grants, conference fees, marketing assistance and/or free medical equipment between 1998 and 2006 in violation of the anti-kickback law, and then the hospitals billed Medicare, DOJ alleged.
Read more